Everyone Wants to Live Longer. Figuring Out How Will Take Years—and Billions of Dollars (Barrons)

The story (below) is correct, if you don’t take into consideration all the data on rapamycin, as well as canagliflozin and acarbose, etc…

Scores of longevity products and treatments are in the pipeline.

The investing world is pondering if the business of longevity has legs.

Advances in genetics and cellular biology have given scientists a more detailed picture of why and how we age. Now biotech start-ups are trying to use that knowledge to keep people healthier as they grow older with the aim of eventually extending the human life span.

Scores of products and treatments are in the pipeline, including drugs designed to rev up metabolism or stop muscle loss in the elderly; therapeutics that rejuvenate aging cells; and new treatments for cancer, one of many diseases that become more prevalent as we age.

Few of these treatments have been approved by regulators, nor are they likely to be for another five or 10 years as new drugs go through trials. “The most important thing is to stay alive for another 10 years because by then we will definitely have an effect” on aging, says Jim Mellon, founder of Juvenescence, which is both developing its own longevity treatments and investing in other longevity biotechs.

Among other things, Juvenescence is developing ketone-based therapies for the treatment of heart disease. Ketones are an energy source that the body uses for fuel during long periods of exercise or fasting.

Longevity investments soared from $525 million in 2013 to $9.26 billion in 2021, according to Longevity.Technology, a website that publishes news and statistics on the industry. The high point came in January 2022 with the $3 billion launch of Altos Labs, which has a lofty goal of “transforming medicine with cellular rejuvenation programming.” Altos is researching the use of stem cells to rejuvenate cells. Amazon.com founder Jeff Bezos is among the company’s backers, according to numerous reports, though the Altos isn’t confirming that.

Investments in the longevity industry, along with funding for biotechs of all stripes, have slumped amid rising interest rates and economic worries. Last year saw $3.01 billion in investments, according to Longevity.Technology.

Full story here: https://archive.ph/YS236